Health, Wall Street, BI Prime, Dispensed, Biotech, IPO, Healthcare, Strategy,

The CEO of 2019’s biggest biotech IPO told us how he’s upending the ‘same old corporate approach’ in healthcare with a stripped down and cost-conscious model

By

BridgeBio BridgeBio just debuted on the stock market with a market value of $3.3 billion. It’s the biggest biotech IPO of the year so far.  BridgeBio was founded with a cost-conscious ethos, because the "same old corporate approach" in biopharma wouldn’t meet the needs of BridgeBio’s rare disease-focused model, CEO and founder Neil Kumar said. […]

MustHaves.LA a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for us to earn fees by linking to Amazon.com and affiliated sites.